- Home
- LLY vs JNJ Comparison
LLY vs JNJ Comparison
Compare LLY & JNJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LLY | JNJ |
|---|---|---|
| Founded | 1876 | 1886 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 979.6B | 542.4B |
| IPO Year | 2007 | 2003 |
Fundamental Metrics
Financial Performance| Metric | LLY | JNJ |
|---|---|---|
| Price | $1,252.74 | $272.76 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 19 | 20 |
| Target Price | ★ $1,218.84 | $238.20 |
| AVG Volume (30 Days) | 2.1M | ★ 6.6M |
| Earning Date | 04-30-2026 | 04-14-2026 |
| Dividend Yield | 0.81% | ★ 2.36% |
| EPS Growth | ★ 95.99 | 90.50 |
| EPS | ★ 16.19 | 4.41 |
| Revenue | ★ $65,179,000,000.00 | N/A |
| Revenue This Year | $27.15 | $6.63 |
| Revenue Next Year | $16.04 | $7.43 |
| P/E Ratio | $77.08 | ★ $61.91 |
| Revenue Growth | ★ 44.70 | N/A |
| 52 Week Low | $712.05 | $173.33 |
| 52 Week High | $1,292.65 | $276.47 |
Technical Indicators
Market Signals| Indicator | LLY | JNJ |
|---|---|---|
| Relative Strength Index (RSI) | 59.42 | 61.45 |
| Support Level | $1,148.95 | $247.97 |
| Resistance Level | N/A | $274.90 |
| Average True Range (ATR) | 36.82 | 4.89 |
| MACD | 5.22 | 0.73 |
| Stochastic Oscillator | 72.88 | 74.94 |
Price Performance
Historical ComparisonAbout LLY Eli Lilly and Company
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
About JNJ Johnson & Johnson
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.